Carlsmed Lifts Sales Forecast To $78 Million–$80 Million After 65% Quarterly Growth

Surgeon adoption expanded, but executive-transition and legal costs helped push quarterly expenses to $29.4 million.

Share
Carlsmed Lifts Sales Forecast To $78 Million–$80 Million After 65% Quarterly Growth

Carlsmed, which develops surgical planning software and custom implants for spine fusion, posted 65% sales growth to $21.6 million in the third quarter, versus $13.1 million a year earlier, according to Tuesday's SEC filing. It raised its annual revenue outlook to $78 million–$80 million from $74 million–$78 million.

More Surgeons, Higher Sales Targets

The new revenue outlook implies growth of more than 56% at the midpoint against 2025. For the first nine months, sales reached $56.6 million, compared with $35.3 million a year earlier.

Mike Cordonnier, Carlsmed's chairman and CEO, said, "we grew our surgeon user base by more than 60% over the prior year."

Carlsmed's aprevo platform combines patient imaging and AI to design surgical plans and implants fitted to individual anatomy for lower-back and neck surgery. It sells implant devices to hospitals and ambulatory surgical centers through sales staff and independent agents, principally in the U.S. Surgical kits contain customized implants and disposable instruments.

Expenses Outrun Gross Profit

Carlsmed retained more of each sales dollar after product costs: its gross margin rose to 77.3% from 75.9%. Gross profit increased to $16.7 million from $9.9 million.

Operating expenses nevertheless climbed to $29.4 million from $19.0 million. That included $2.8 million tied to executive transitions and the expected resolution of certain legal matters. Sales and marketing cost $13.0 million, against $9.6 million; research and development spending reached $6.4 million, against $4.4 million; and administration cost $10.0 million, against $4.9 million.

The net loss widened to $12.2 million, or $0.45 per share, from $8.5 million, or $0.40 per share. Adjusted EBITDA—a measure excluding interest, taxes, depreciation and selected other costs—showed a smaller loss of $7.3 million versus $8.2 million.

Those measures exclude different costs. The adjusted EBITDA calculation removed $2.5 million in stock-based pay, compared with $0.7 million a year earlier, as well as executive-transition and legal-settlement charges. For the first nine months, the adjusted EBITDA loss widened to $23.5 million from $19.9 million.

A Broader Lumbar Offering

October's launch of the aprevo Lumbar Bi-lateral Posterior System expanded the product lineup. Carlsmed estimates that the system addresses approximately 30,000 U.S. lumbar fusion procedures annually. A Medicare payment rule effective October 1 increased reimbursement for inpatient aprevo lumbar procedures.

The company also changed its leadership team. Richard Heppenstall's appointment as finance chief was announced September 28, following Jeff Bertolini's promotion to operating chief on September 8. Carlsmed also added Tony Jarc as chief product and AI officer.

Carlsmed ended September with $80.3 million across cash, restricted cash, short-term investments and marketable securities. Its higher sales target now sits alongside a business that still reported losses on both standard accounting and adjusted EBITDA measures.

Sources